Please login to the form below

Not currently logged in
Email:
Password:

Grifols

This page shows the latest Grifols news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

The setback is also a blow to Spanish drugmaker Grifols, which bought into the phase III programme for Linhaliq in 2013 ago and funded the late-stage trials.

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    2, 180. Hologic (US). Grifols (Spain). Asset acquisition. Nucleic Acid Testing (NAT) technology for R&D and manufacturing of assays and instruments for blood screening. ... The Gold award is won by Grifols, with a 13.6% rise in share price since the

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    1, 800. Novartis / Grifols. Acquisition. Novartis divestment of its blood transfusion testing unit.

  • Pharma deals during November 2013 Pharma deals during November 2013

    In the same vein, Novartis is reviewing its strategy and announced the divestment of its blood transfusion diagnostics unit for $1.7bn to Grifols as part of its ongoing business review.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics